Codexis : Corporate Presentation Dec 2020

Corporate Presentation

December 2020

Forward Looking Statements

• • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" or the negative of these terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

• • Other factors that could materially affect actual results or levels of activity, performance or achievement can be found in Codexis' Form 10-K for the period ended December 31, 2019 filed with the SEC on February 28, 2020 and the Form 10-Q filed for each quarter ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 8, 2020, August 7, 2020 and November 6, 2020, respectively, including under the caption "Risk Factors," and Codexis' other current and periodic reports filed with the SEC. If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results or levels of activity, performance or achievement may vary significantly from what we projected.

• • Our logo, "Codexis," "CodeEvolver®," "X", and other trademarks or service marks of Codexis, Inc. appearing in this presentation are the property of Codexis, Inc. This presentation contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

Codexis' Vision and Mission

01010

We engineer enzymes to improve health… of people and the planet

CodeEvolver® Platform: Scaling & Improving for 18+ Years

Constantly Accelerating Product Discovery Engine

• • Capacity: 16 parallel discovery teams, & growing

• • Unique Big Data: structuresreal world performance

• • Massive Data: generate & map 100k's of enzymes / yr

• • Machine Learning: 18+ yrs improving in silico predictions

• • Compounding Improvements: each building on the last

• • Translatable: from past successes to new markets

• • Protected: >1500 patents and applications & growing

"What Codexis has done is crack the massive bioinformatics challenge"

- Mark Buswell, Head of Advanced Manufacturing Technologies, GSK

4